miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 17, 2026

Earnings live: eToro surges after Q4 profit beat, Medtronic stumbles, DTE Energy pops

View original at finance.yahoo.com
Earnings live: eToro surges after Q4 profit beat, Medtronic stumbles, DTE Energy pops The fourth quarter earnings season is entering the final stretch…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Equinix issued strong annual revenue guidance on the back of continued artificial intelligence demand

    80% confidence
  • Analysts were expecting an 8.3% jump in earnings per share heading into Q4 reporting, down from Q3's 13.6% growth rate

    80% confidence
  • Airbnb forecast Q1 revenue between $2.59 billion and $2.63 billion, above analyst estimates of $2.52 billion

    80% confidence
  • Companies missing estimates have seen their stock fall 2% on average this earnings period, less than the 2.8% decline seen over the last five years

    80% confidence
  • Coinbase has seen $420 million of transaction revenue in Q1 through Feb. 10

    80% confidence
  • Baxter forecast 2026 annual profit below Wall Street estimates, citing persistent problems from hurricane-related issues at manufacturing plant

    80% confidence
  • Coinbase customer funds are safe despite exchange issues

    80% confidence
  • As GLP-1 adoption grows, consumers eat fewer calories and the mix of what they eat changes; McDonald's is factoring in changing diet preferences

    80% confidence
  • Crocs issued full-year 2026 profit guidance of $12.88 to $13.35 per share, beating analyst estimates of $11.92

    80% confidence
  • Cisco sees strong, broad-based demand for technology solutions and remains focused on capturing significant opportunities ahead

    80% confidence
  • If the 13.2% growth rate holds, it would represent the 10th consecutive quarter of annual earnings growth and the fifth consecutive quarter of double-digit growth for the S&P 500

    80% confidence
  • McDonald's has made significant progress on value and affordability platforms and will not lose on value

    80% confidence
  • Cisco raised full-year EPS guidance to $3.00-$3.08 on revenue of $61.2-$61.7 billion, below Street estimates of $3.12 EPS on $62.1 billion revenue

    80% confidence
  • Coinbase expects Q1 subscription and services revenue of $550 million to $630 million, compared to $710 million to $790 million in Q4

    80% confidence
  • 74% of S&P 500 companies have reported results as of Feb. 13, with blended earnings growth at 13.2%

    80% confidence
  • The Extra Value Meal deal is fundamental in the current environment; many locations would keep it even as corporate support is pulled back in Q1

    80% confidence

Data points we hold from this source

Coinbase Global · net income1300 million_USD
Coinbase Global · net income-667 million_USD
Coinbase Global · revenue710-790 million_USD
Coinbase Global · revenue550-630 million_USD
Coinbase Global · revenue1.78 billion_USD

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Earnings live: eToro surges after Q4 profit beat, Medtronic stumbles, DTE Energy pops — Source | Via News | es.VIA.NEWS